Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.90 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.90 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL16752517 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL612484 | 1.00 | — | — | |
| Fumaric Acid SCHEMBL8557756 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL793773 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL793772 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL10796092 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL7337222 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL4617429 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL12474192 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL363367 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729061-A1 | USE OF AKT INHIBITOR IN PREPARATION OF DRUG FOR PREVENTING OR TREATING BREAST CANCER | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| CN-121586576-A | Application of AKT inhibitor in preparation of medicines for preventing or treating breast cancer | 南京正大天晴制药有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-120058671-A | Vonoprazan hemi-fumarate and preparation method thereof | 上海皓元医药股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2024255883-A1 | USE OF AKT INHIBITOR IN PREPARATION OF DRUG FOR PREVENTING OR TREATING BREAST CANCER | 南京正大天晴制药有限公司 | 2024-12-19 | — | — | WO | claimed |
| WO-2024255830-A1 | USE OF AKT INHIBITOR IN PREPARATION OF DRUG FOR PREVENTING OR TREATING OVARIAN CANCER | 南京正大天晴制药有限公司 | 2024-12-19 | — | — | WO | claimed |
| WO-2024138007-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| EP-3971177-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2024-06-26 | — | — | EP | claimed |
| CN-117624124-A | Vonolamine hemi-fumarate crystal compound, preparation method and application | 浙江华理生物制药有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117510500-A | Preparation method of asperazepanones alkaloid and application of asperazepanones alkaloid as anti-inflammatory drug | 中国海洋大学 | 2024-02-06 | — | — | CN | claimed |
| EP-3515451-B2 | PHARMACEUTICAL COMPOSITION | MEXICHEM FLUOR SA DE CV (MX) | 2023-10-04 | — | — | EP | claimed |
| WO-2001089492-A1 | NOVEL COMPOSITION | ASTRAZENECA AB (SE) | 2001-11-29 | — | — | WO | claimed |
| WO-2001089491-A1 | NOVEL PROCESS | ASTRAZENECA AB (SE) | 2001-11-29 | — | — | WO | claimed |
| US-6299863-B1 | REDUCED ADVERSE EFFECTS, HAVING A LOW INCIDENCE OF THE DEVELOPMENT OF TOLERANCE AND HAVING INCREASED DURATION OF ACTION | SEPRACOR INC. | 2001-10-09 | — | — | US | claimed |
| WO-2001070198-A1 | STABILIZED DRY POWDER FORMULATIONS | DURA PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| CN-1305380-A | Use of composition comprising Formoterol and Budesonide for prevention or treatment of acute condition of asthma | ASTRA ZENECA AKTIEBOLAF (SE) | 2001-07-25 | — | — | CN | claimed |
| WO-2000053187-A1 | NEW COMBINATION OF FORMOTEROL AND MOMETASONE IN A PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISORDERS, SUCH AS ASTHMA, RHINITIS AND COPD | ASTRAZENECA AB (SE) | 2000-09-14 | — | — | WO | claimed |
| WO-2000053188-A1 | NEW COMBINATION OF R,R-FORMOTEROL AND BUDESONIDE IN A PHARMACEUTICAL COMPOSITION USEFUL FOR TREATING RESPIRATORY DISORDERS, SUCH AS ASTHMA, RHINITIS AND COPD | ASTRAZENECA AB (SE) | 2000-09-14 | — | — | WO | claimed |
| US-5972919-A | FORMOTEROL FUMARATE DIHYDRATE OR A SOLVATE AND BUDESONIDE TOGETHER OR SIMULTANEOUSLY INHALED IN THE FORM OF DRY POWDER TO TREAT ASTHMA | ASTRA AKTIEBOLAG (SE) | 1999-10-26 | — | — | US | claimed |
| CN-1186428-A | Process for the preparation of particles suitable for inhalation use | ASTRA AB (SE) | 1998-07-01 | — | — | CN | claimed |
| US-5674860-A | ADMINISTERING MEASURED AMOUNTS OF FORMOTEROL(OR ITS SALTS OR SOLVATES) AND BUDESONIDE BY INHALATION | ASTRA AKTIEBOLAG (SE) | 1997-10-07 | — | — | US | claimed |